PMID- 27741522
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20220321
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 11
DP  - 2017 Mar 14
TI  - The influence of PSA autoantibodies in prostate cancer patients: a prospective 
      clinical study-II.
PG  - 17643-17650
LID - 10.18632/oncotarget.12620 [doi]
AB  - The U.S. Preventive Services Task Force (USPSTF) has recommended against 
      PSA-based screening for prostate cancer due to potential possibilities of 
      false-results. Since no alternative test is available to replace it, we have 
      initiated a trial with the purpose of establishing whether Galectin-3 (Gal-3) 
      serum level and/or the patients' immune response to PSA and Gal-3 antigens could 
      complement the PSA test as diagnostic tools for prostate cancer patients. A 
      blind, prospective, single institution, pilot study was conducted. A total of 95 
      men were recruited and classified into 5 different groups: healthy controls 
      (Group1), newly diagnosed patients (Group2), no recurrence after local therapy 
      (Group3), rising PSA after local therapy (Group4), and metastatic patients 
      (Group5). The primary endpoints were the levels of serum PSA, PSA autoantibodies 
      (AAPSA), Gal-3, and Gal-3 autoantibodies (AAGal-3). Data were analyzed by 
      Spearman's rank correlation (rho) and least squares linear regression modeling. 
      The expression levels of PSA, AAPSA, Gal-3, and AAGal-3 were determined in both 
      healthy controls and prostate cancer patients. Negative correlations were 
      observed between PSA and AAPSA levels among all 95 men combined (rho = -0.321, P 
      = 0.0021; fitted slope -0.288, P = 0.0048), and in metastatic patients (rho = 
      -0.472, P = 0.0413; fitted slope -1.145, P = 0.0061). We suggest an association 
      between PSA and AAPSA, whereby the AAPSA may alter PSA levels. It provides a 
      novel outlook for prostate cancer diagnosis, and should serve as a basis for an 
      all-inclusive diagnostic trial centering on patients with metastasis.
FAU - Nakajima, Kosei
AU  - Nakajima K
AD  - Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
AD  - Department of Pathology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
FAU - Heilbrun, Lance K
AU  - Heilbrun LK
AD  - Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
AD  - Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, 
      Michigan, USA.
FAU - Smith, Daryn
AU  - Smith D
AD  - Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
AD  - Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, 
      Michigan, USA.
FAU - Hogan, Victor
AU  - Hogan V
AD  - Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
AD  - Department of Pathology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
FAU - Raz, Avraham
AU  - Raz A
AD  - Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
AD  - Department of Pathology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
FAU - Heath, Elisabeth
AU  - Heath E
AD  - Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne 
      State University, Detroit, Michigan, USA.
LA  - eng
GR  - P30 CA022453/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Galectin 3)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Autoantibodies/*blood
MH  - Autoantigens/immunology
MH  - Biomarkers, Tumor/*blood/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Galectin 3/immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prostate-Specific Antigen/blood/*immunology
MH  - Prostatic Neoplasms/*blood/immunology
PMC - PMC5392275
OTO - NOTNLM
OT  - Galectin-3
OT  - PSA autoantibody
OT  - PSA test
OT  - false-results
OT  - prostate cancer
COIS- CONFLICTS OF INTEREST There are no potential conflicts to declare.
EDAT- 2016/10/16 06:00
MHDA- 2017/09/21 06:00
PMCR- 2017/03/14
CRDT- 2016/10/15 06:00
PHST- 2016/08/17 00:00 [received]
PHST- 2016/10/07 00:00 [accepted]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
PHST- 2016/10/15 06:00 [entrez]
PHST- 2017/03/14 00:00 [pmc-release]
AID - 12620 [pii]
AID - 10.18632/oncotarget.12620 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Mar 14;8(11):17643-17650. doi: 10.18632/oncotarget.12620.